<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03225417</url>
  </required_header>
  <id_info>
    <org_study_id>X16082</org_study_id>
    <nct_id>NCT03225417</nct_id>
  </id_info>
  <brief_title>Ixazomib in Combination With Sirolimus and Tacrolimus in the Prophylaxis of Chronic Graft-versus-host Disease.</brief_title>
  <official_title>Phase Ib/II Trial to Evaluate Safety and Efficacy of Oral Ixazomib in Combination With Sirolimus and Tacrolimus in the Prophylaxis of Chronic Graft-versus-host Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic hematopoietic stem cell transplantation (HTC) is the only curative option for many
      patients with hematologic malignancies but &gt;50% of this patients will develop extensive
      chronic graft-versus-host disease (cGVHD), which remains the most important complication
      after HTC.

      Classically, the most effective strategies to prevent GVHD have not improved survival;
      therefore, the new strategies are being sought.

      This study is designed in two phases: the main objective for phase I study is the more
      suitable dose for ixazomib search. Phase II study is designed to evaluate the efficacy of
      ixazomib at the doses stablished in phase I.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design is based on a phase I / II trial in seven Spanish hospitals.

      In the phase I, a number of 3 to 24 patients will be included to evaluate the optimal dose of
      ixazomib in combination with sirolimus and tacrolimus.

      In the phase II, a total number of 130 patients will be randomized to receive ixazomib or the
      best medical recommendation added in order to evaluate the efficacy of ixazomib.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 16, 2017</start_date>
  <completion_date type="Anticipated">May 27, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 27, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To identify the optimal dose and evaluate ixazomib tolerance used after transplantation for the phase I study</measure>
    <time_frame>3 months after trasplantation (a total of 3 cycles of 28 days lenght of study treatment)</time_frame>
    <description>Identifying maximun tolerated dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of ixazomib for phase II study</measure>
    <time_frame>9 months after trasplantation (a total of 9 cycles of 28 days lenght of study treatment)</time_frame>
    <description>Presence of moderate plus severe Chronic Graft-versus-host Disease according to NIH scale in patients receiving the maximum tolerated dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event free survival</measure>
    <time_frame>Just after the time of transplantation and 1 and/or 2 years after transplantation</time_frame>
    <description>Quantification of time of event free survival for patients receiving the maximum tolerated dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event immune recovery</measure>
    <time_frame>Just after the time of transplantation and 1 and/or 2 years after transplantation</time_frame>
    <description>Quantification of time of event immune recovery in patients receiving the maximum tolerated dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exposure to immunosuppressive treatment</measure>
    <time_frame>1 and/or 2 years after transplantation</time_frame>
    <description>Evaluation of needs of aditional permitted immunosuppressive treatment administered as concomitant medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall disease free survival</measure>
    <time_frame>2 years after transplantation</time_frame>
    <description>Quantification of time of overall survival after study treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixazomib + Tacrolimus + Sirolimus Phase I: Ixazomib doses in this study is 3 to 4 mg of ixazomib on day +1, +8 and +15.
Tacrolimus at a dose of 0.02 mg/kg/day and then 0.06 mg/kg/day. Sirolimus at a dose of 6 mg on day -5 and then 4 mg per day.
Phase II: Starting Dose of Ixazomib according to phase I. Tacrolimus at a dose of 0.02 mg/kg/day and then 0.06 mg/kg/day. Sirolimus at a dose of 6 mg on day -5 and then 4 mg per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Tacrolimus + Sirolimus Tacrolimus at a dose of 0.02 mg/kg/day and then 0.06 mg/kg/day. Sirolimus at a dose of 6 mg on day -5 and then 4 mg per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixazomib</intervention_name>
    <description>Ixazomib capsules. Phase I: Starting dose of Ixazomib: 3.0 or 4.0 mg by day +1, +8 and +15. Phase II: Starting Dose of Ixazomib: Maximum tolerated dose from Phase I.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>X16082</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus at a dose of 0.02 mg/kg/day and then 0.06 mg/kg/day.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Sirolimus oral solution. Starting 6 mg orally on day -5 and continued 4 mg per day. This drugs should be slowly tapered starting 3 months posttransplant in order to stop them at 9 to 12 months posttransplant according to physician criteria.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients 18 years or older.

          2. Patients having received reduced intensity conditioning peripheral blood allogeneic
             stem cell transplantation.

          3. Patients undergoing hematopoietic stem cell transplant from a matched or a single
             mismatched related or unrelated donor as definition accepted by protocol.

          4. Patients receiving Graft-versus-host Disease prophylaxis with sirolimus and tacrolimus
             and on stable levels during the last 2 weeks before inclusion.

          5. Voluntary written consent must be given before performance of any study related
             procedure.

          6. Female patients who accomplish with requisitions for not possibility of pregnancy
             (menopausal, effective methods of contraception), as detailed by protocol.

          7. Eastern Cooperative Oncology Group performance status and/or other performance status
             0, 1, or 2.

          8. Patients must meet the following clinical laboratory criteria:

               -  Absolute neutrophil count 1,000/mm3 and platelet count 75,000/mm3. Platelet
                  transfusions to help patients meet eligibility criteria are not allowed within 3
                  days before study enrollment.

               -  Total bilirubin 1.5 the upper limit of the normal range .

               -  Alanine aminotransferase and aspartate aminotransferase 3 upper limit of the
                  normal range.

               -  Calculated creatinine clearance 30 mL/min.

          9. Ability to swallow and tolerate oral medication.

         10. Absence of gastrointestinal symptoms that precludes oral intake and absorption.

         11. Off antibiotics and amphotericin B formulations, voriconazole or other anti-fungal
             therapy for the treatment of active proven, probable or possible infections.

        Exclusion Criteria:

          1. Female patients who are lactating or have a positive serum pregnancy test during the
             screening period.

          2. Major surgery within 14 days before enrollment.

          3. Central nervous system involvement with malignant cells.

          4. Uncontrolled infection within 14 days before study enrollment.

          5. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled
             hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure,
             unstable angina, or myocardial infarction within the past 6 months.

          6. Systemic treatment, within 14 days before the first dose of ixazomib, with strong
             Cytochrome P450, family 3, subfamily A inducers (rifampin, rifapentine, rifabutin,
             carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort.

          7. Ongoing or active systemic infection, active hepatitis B or C virus infection, or
             known human immunodeficiency virus positive.

          8. Any serious medical or psychiatric illness that could, in the investigator's opinion,
             potentially interfere with the completion of treatment according to this protocol.

          9. Known allergy to any of the study medications, their analogues, or excipients in the
             various formulations of any agent.

         10. Diagnosed or treated for another malignancy within 2 years before study enrollment or
             previously diagnosed with another malignancy and have any evidence of residual
             disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are
             not excluded if they have undergone complete resection.

         11. Patient has Grade 1 peripheral neuropathy.

         12. Participation in other clinical trials, including those with other investigational
             agents not included in this trial, within 30 days of the start of this trial and
             throughout the duration of this trial.

         13. Patients that have previously been treated with ixazomib, or participated in a study
             with ixazomib whether treated with ixazomib or not.

         14. Active Graft versus host disease at the time of inclusion: patients are allowed to be
             included if acute Graft-versus-host Disease is in complete remission and are receiving
             systemic steroids at &lt; 0.25 mg / kg.

         15. Active hematologic malignancy at the time of inclusion.

         16. Active microangiopathy at the time of inclusion (according to International Working
             Group criteria).

         17. Gastrointestinal disease or procedure than can interfere with oral absorption ,
             intolerance to the ixazomib or difficulty to swallow.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose-Antonio Perez-Simon, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospitales Universitarios Virgen del Rocío</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose-Antonio Perez-Simon, MD-PhD</last_name>
    <phone>0034955013414</phone>
    <email>josea.perez.simon.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clara Rosso, MD</last_name>
    <phone>0034955013414</phone>
    <email>claram.rosso.sspa@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICO- Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M. Christelle Ferra Coll, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>M. Christelle Ferra Coll, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmen Martínez, MD-Phd</last_name>
      <email>CMARTI@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Carmen Martínez, MD-Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jorge Sierra Gil, MD-Phd</last_name>
      <email>jsierra@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Jorge Sierra Gil, MD-Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall D´Hebrón</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Valcarcel Ferreira, MD-Phd</last_name>
      <email>dvalcarcel.vhebron@me.com</email>
    </contact>
    <investigator>
      <last_name>David Valcarcel Ferreira, MD-Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucía Lopez del Corral, MD-PhD</last_name>
      <email>lucialopezcorral@usal.es</email>
    </contact>
    <investigator>
      <last_name>Lucía Lopez del Corral, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose-Antonio Perez-Simon, MD-PhD</last_name>
      <phone>0034955013260</phone>
      <phone_ext>0034</phone_ext>
      <email>josea.perez.simon.sspa@juntadeandalucia.es</email>
    </contact>
    <contact_backup>
      <last_name>Clara M. Rosso, MD</last_name>
      <phone>0034955013414</phone>
      <phone_ext>0034</phone_ext>
      <email>claram.rosso.sspa@juntadeandalucia.es</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Solano Vercet, MD-Phd</last_name>
      <email>solano_car@gva.es</email>
    </contact>
    <investigator>
      <last_name>Carlos Solano Vercet, MD-Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ixazomib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Ixazomib</mesh_term>
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized data for primary and secondary variables is planned to be shared with all participants within 6 months of data completion.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

